Pharmacokinetics of tazarotene and acitretin in psoriasis

References

• Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014 Mar;70:512–516.
   PubMed Web of Science ®Google Scholar
• Benjegerdes KE, Hyde K, Kivelevitch D, et al. Pustular psoriasis: pathophysiology and current treatment perspectives. Psoriasis. 2016;6:131–144.
   PubMed Web of Science ®Google Scholar
• Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol. 2009 Sep;23(Suppl 1):15–21.
   PubMed Web of Science ®Google Scholar
• Henes JC, Ziupa E, Eisfelder M, et al. High prevalence of psoriatic arthritis in dermatological patients with psoriasis: a cross-sectional study. Rheumatol Int. 2014;34:227–234.
   PubMed Web of Science ®Google Scholar
• Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–407.
   PubMed Web of Science ®Google Scholar
• Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol Clin. 2015 Jan;33:13–23.
   PubMed Web of Science ®Google Scholar
• Lowes MA, Suarez-Farinas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol. 2014;32:227–255.
   PubMed Web of Science ®Google Scholar
• Perera GK, Di Meglio P, Nestle FO. Psoriasis. Annu Rev Pathol. 2012;7:385–422.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Bruce AT, Gudjonsson JE, et al. Induction of IL-17+ T cell trafficking and development by IFN-gamma: mechanism and pathological relevance in psoriasis. J Immun. 2008 Oct 1;181:4733–4741.
   PubMed Web of Science ®Google Scholar
• Donetti E, Cornaghi L, Gualerzi A, et al. An innovative three-dimensional model of normal human skin to study the proinflammatory psoriatic effects of tumor necrosis factor-alpha and interleukin-17. Cytokine. 2014;68:1–8.
   PubMed Web of Science ®Google Scholar
• Lockmann A, Schon MP. TNF alpha-induced leukocyte-endothelial cell interactions show marked interindividual differences independent of the clinical response to adalimumab. Exp Dermatol. 2014 Feb;23:133–134.
   PubMed Web of Science ®Google Scholar
• Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, et al. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol. 1994 Apr;30:581–590.
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-alpha levels in patients with psoriasis before, during and after psoralen-ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol. 2010;163:1282–1290.
   PubMed Web of Science ®Google Scholar
• Teige I, Hvid H, Svensson L, et al. Regulatory T cells control VEGF-dependent skin inflammation. J Invest Dermatol. 2009;129:1437–1445.
   PubMed Web of Science ®Google Scholar
• Elias PM, Arbiser J, Brown BE, et al. Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psoriasis. Am J Pathol. 2008;173:689–699.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol. 2010;62:114–135.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–659.
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–850.
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol. 2009;61:451–485.
   PubMed Web of Science ®Google Scholar
• Wolf G. A history of vitamin A and retinoids. FASEB J. 1996 Jul;10:1102–1107.
   PubMedGoogle Scholar
• McCollum E, Davis M. The neccesity of certain lipids during growth. J Biol Chem. 1913;15:167–175.
   Google Scholar
• Wolbach SB, Howe PR. TIssue changes following deprivation of fat-soluble a vitamin. J Exp Med. 1925 Nov 30;42:753–777.
   PubMedGoogle Scholar
• Khalil S, Bardawil T, Stephan C, et al. Retinoids: a journey from the molecular structures and mechanisms of action to clinical uses in dermatology and adverse effects. J Dermatolog Treat. 2017;28:684–696.
   PubMed Web of Science ®Google Scholar
• Bushue N, Wan YJ. Retinoid pathway and cancer therapeutics. Adv Drug Deliv Rev. 2010 Oct 30;62:1285–1298.
   PubMed Web of Science ®Google Scholar
• Pilkington T, Brogden RN. Acitretin. Rev Pharmac Therapuse Drugs. 1992 Apr;43:597–627.
   Google Scholar
• Chandraratna RA. Rational design of receptor-selective retinoids. J Am Acad Dermatol. 1998 Oct;39:S124–8.
   PubMed Web of Science ®Google Scholar
• Fisher GJ, Talwar HS, Xiao JH, et al. Immunological identification and functional quantitation of retinoic acid and retinoid X receptor proteins in human skin. J Biol Chem. 1994 Aug 12;269:20629–20635.
   PubMed Web of Science ®Google Scholar
• Weindl G, Roeder A, Schafer-Korting M, et al. Receptor-selective retinoids for psoriasis: focus on tazarotene. Am J Clin Dermatol. 2006;7:85–97.
   PubMed Web of Science ®Google Scholar
• Love JM, Gudas LJ. Vitamin A, differentiation and cancer. Curr Opin Cell Biol. 1994 Dec;6:825–831.
   PubMed Web of Science ®Google Scholar
• Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoic acid receptor alpha. J Biol Chem. 1995 Jan 13;270:923–927.
   PubMed Web of Science ®Google Scholar
• Kamei Y, Xu L, Heinzel T, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. Cell. 1996 May 3;85:403–414.
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1:327–348.
   PubMed Web of Science ®Google Scholar
• Nagpal S, Thacher SM, Patel S, et al. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acid receptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ. 1996;7:1783–1791.
   PubMedGoogle Scholar
• Duvic M, Nagpal S, Asano AT, et al. Molecular mechanisms of tazarotene action in psoriasis. J Am Acad Dermatol. 1997;37:S18–S24.
   PubMed Web of Science ®Google Scholar
• Qin X, Chen C, Zhang Y, et al. Acitretin modulates HaCaT cells proliferation through STAT1- and STAT3-dependent signaling. Saudi Pharm J. 2017;25:620–624.
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhu L, Feng Y, et al. Effects of acitretin on proliferative inhibition and RANTES production of HaCaT cells. Arch Dermatol Res. 2008;300:575–581.
   PubMed Web of Science ®Google Scholar
• Niu X, Cao W, Ma H, et al. Acitretin exerted a greater influence on T-helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris. J Dermatol. 2012;39:916–921.
   PubMed Web of Science ®Google Scholar
• Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet. 1999 Oct;37:273–287.
   PubMed Web of Science ®Google Scholar
• Marks R. Pharmacokinetics and safety review of tazarotene. J Am Acad Dermatol. 1998 Oct;39:S134–8.
   PubMed Web of Science ®Google Scholar
• Madhu C, Duff S, Baumgarten V, et al. Metabolic deesterification of tazarotene in human blood and rat and human liver microsomes. J Pharm Sci. 1997;86:972–974.
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol. 1997;37:85–92.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol. 1998;38:705–711.
   PubMed Web of Science ®Google Scholar
• Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol. 2000 Aug;43:S31–5.
   PubMed Web of Science ®Google Scholar
• Marks R. Early clinical development of tazarotene. Br J Dermatol. 1996 Oct;135(Suppl 49):26–31.
   PubMedGoogle Scholar
• Larsen FG, Jakobsen P, Larsen CG, et al. Single dose pharmacokinetics of etretin and etretinate in psoriatic patients. Pharmacol Toxicol. 1987;61:85–88.
   PubMedGoogle Scholar
• Meyer E, De Bersaques J, Lambert WE, et al. Skin, adipose tissue and plasma levels of acitretin with rare occurrence of esterified acitretin during long-term treatment. Acta Derm Venereol. 1993;73:113–115.
   PubMed Web of Science ®Google Scholar
• Larsen FG, Jakobsen P, Larsen CG, et al. Pharmacokinetics of etretin and etretinate during long-term treatment of psoriasis patients. Pharmacol Toxicol. 1988 Mar;62:159–165.
   PubMedGoogle Scholar
• Larsen FG, Jakobsen P, Knudsen J, et al. Conversion of acitretin to etretinate in psoriatic patients is influenced by ethanol. J Invest Dermatol. 1993;100:623–627.
   PubMed Web of Science ®Google Scholar
• Larsen FG, Jakobsen P, Eriksen H, et al. The pharmacokinetics of acitretin and its 13-cis-metabolite in psoriatic patients. J Clin Pharmacol. 1991;31:477–483.
   PubMed Web of Science ®Google Scholar
• Rubio F, Jensen BK, Henderson L, et al. Disposition of [14C]acitretin in humans following oral administration. Drug Metab Dispos. 1994;22:211–215.
   PubMed Web of Science ®Google Scholar
• Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther. 2000 Oct;22:1225–1238.
   PubMed Web of Science ®Google Scholar
• Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol. 2003;4:197–202.
   PubMed Web of Science ®Google Scholar
• Gold LS, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79:287–293.
   PubMed Web of Science ®Google Scholar
• Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis. 2001 Nov;68:355–358.
   PubMed Web of Science ®Google Scholar
• Rigopoulos D, Gregoriou S, Katsambas A. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study. Acta Derm Venereol. 2007;87:167–168.
   PubMed Web of Science ®Google Scholar
• Weinstein GD, Koo JYM, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003 May;48:760–767.
   PubMed Web of Science ®Google Scholar
• FDA. Medical review. Mulicenter, double-blind, randomized, vehicle-controlled study of the safety and efficacy of 0.05% and 0.1% tazarotene creams applied once daily for 12 weeks, with a 12-week follow-up, in the treatment of plaque psoriasis (Study #190168-016C) [initiated 12/29/97, completed 1/22/99].
   Google Scholar
• FDA. Medical review. Mulicenter, double-blind, randomized, vehicle-controlled study of the safety and efficacy of 0.05% and 0.1% tazarotene creams applied once daily for 12 weeks, with a 12-week follow-up, in the treatment of plaque psoriasis (Study #190168-017C) [initiated 12/30/97, completed 10/16/98].
   Google Scholar
• FDA. Medical review. Study #168-125-8696: safety, efficacy and duration of therapeutic effect of tazarotene (AGN 190168) 0.1% or 0.05% gel applied once daily versus lidex ® 0.05% cream applied twice daily in stable plaque psoriasis.
   Google Scholar
• Gollnick H, Bauer R, Brindley C, et al. Acitretin versus etretinate in psoriasis. Clinical and pharmacokinetic results of a German multicenter study. J Am Acad Dermatol. 1988;19:458–468.
   PubMed Web of Science ®Google Scholar
• Goldfarb MT, Ellis CN, Gupta AK, et al. Acitretin improves psoriasis in a dose-dependent fashion. J Am Acad Dermatol. 1988;18:655–662.
   PubMed Web of Science ®Google Scholar
• Kragballe K, Jansen CT, Geiger JM, et al. A double-blind comparison of acitretin and etretinate in the treatment of severe psoriasis. Res Nordic Multicen Study Acta Dermato-Venereolog. 1989;69:35–40.
   PubMed Web of Science ®Google Scholar
• Lassus A, Geiger JM, Nyblom M, et al. Treatment of severe psoriasis with etretin (RO 10-1670). Br J Dermatol. 1987;117:333–341.
   PubMed Web of Science ®Google Scholar
• Murray HE, Anhalt AW, Lessard R, et al. A 12-month treatment of severe psoriasis with acitretin: results of a Canadian open multicenter study. J Am Acad Dermatol. 1991;24:598–602.
   PubMed Web of Science ®Google Scholar
• Lee JH, Youn JI, Kim TY, et al.A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis. BMC Dermatol. 2016 Jul 25;Vol. 16:11.
   PubMed Web of Science ®Google Scholar
• Buccheri L, Katchen BR, Karter AJ, et al. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133:711–715.
   PubMed Web of Science ®Google Scholar
• Robinson A, Van Voorhees AS, Hsu S, et al. Treatment of pustular psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2012;67:279–288.
   PubMed Web of Science ®Google Scholar
• Sevrain M, Richard MA, Barnetche T, et al. Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereology. 2014 Aug;28(Suppl 5):13–16.
   PubMedGoogle Scholar
• Rosenbach M, Hsu S, Korman NJ, et al. Treatment of erythrodermic psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;62:655–662.
   PubMed Web of Science ®Google Scholar
• Dogra S, Yadav S. Acitretin in psoriasis: an evolving scenario. Int J Dermatol. 2014 May;53:525–538.
   PubMed Web of Science ®Google Scholar
• Ozawa A, Ohkido M, Haruki Y, et al. Treatments of generalized pustular psoriasis: a multicenter study in Japan. J Dermatol. 1999;26:141–149.
   PubMedGoogle Scholar
• Janagond AB, Kanwar AJ, Handa S. Efficacy and safety of systemic methotrexate vs. acitretin in psoriasis patients with significant palmoplantar involvement: a prospective, randomized study. J Eur Acad Dermatol Venereology. 2013 Mar;27:e384–9.
   PubMed Web of Science ®Google Scholar
• Lassus A, Geiger JM. Acitretin and etretinate in the treatment of palmoplantar pustulosis: a double-blind comparative trial. Br J Dermatol. 1988 Dec;119:755–759.
   PubMed Web of Science ®Google Scholar
• Pang ML, Murase JE, Koo J. An updated review of acitretin–a systemic retinoid for the treatment of psoriasis. Expert Opin Drug Metab Toxicol. 2008 Jul;4:953–964.
   PubMed Web of Science ®Google Scholar
• Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar pustulosis: current treatment and future prospects. Am J Clin Dermatol. 2016 Aug;17:349–358.
   PubMed Web of Science ®Google Scholar
• Geiger JM, Czarnetzki BM. Acitretin (Ro 10-1670, etretin): overall evaluation of clinical studies. Dermatologica. 1988;176:182–190.
   PubMedGoogle Scholar
• National Center for Biotechnology Information. PubChem Compound Database; CID=5381, [cited 2018 Jul 8]. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5381
   Google Scholar
• Lee CS, Li K. A review of acitretin for the treatment of psoriasis. Expert Opin Drug Saf. 2009 Nov;8:769–779.
   PubMed Web of Science ®Google Scholar
• Ortiz NE, Nijhawan RI, Weinberg JM. Acitretin. Dermatol Ther. 2013 Sep-Oct;26:390–399.
   PubMed Web of Science ®Google Scholar
• National Center for Biotechnology Information. PubChem Compound Database; CID=5284513, [cited 2018 Jul 8] Available from: https://pubchem.ncbi.nlm.nih.gov/compound/5284513
   Google Scholar
• Lew-Kaya DA, S J, Gg K, et al. Safety and efficacy of a new retinoid gel in the treatment of psoriasis. (Abstract). J Invest Dermatol. 1992;98:705–711.
   Web of Science ®Google Scholar
• Weinstein GD. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis. Br J Dermatol. 1996 Oct;135(Suppl 49):32–36.
   PubMedGoogle Scholar
• Weinstein GD. Tazarotene gel: efficacy and safety in plaque psoriasis. J Am Acad Dermatol. 1997 Aug;37:S33–8.
   PubMed Web of Science ®Google Scholar
• Soriatane (Acitretin) [Medication Guide]. 2017
   Google Scholar
• DiGiovanna JJ, Zech LA, Ruddel ME, et al. Etretinate. ersistent serum levels after long-term therapy. Arch Dermatolog. 1989;125:246–251.
   PubMed Web of Science ®Google Scholar
• Berbis P, Bun H, Geiger JM, et al. Acitretin (RO10-1670) and oral contraceptives: interaction study. Arch Dermatol Res. 1988;280:388–389.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Bagel J, Namak S. Biosimilars for immune-mediated chronic diseases in primary care: what a practicing physician needs to know. Am J Med Sci. 2018 May;355:411–417.
   PubMed Web of Science ®Google Scholar
• Dayal S, Kaura R, Sahu P, et al. Tazarotene gel with narrow-band UVB phototherapy: a synergistic combination in psoriasis. An Bras Dermatol. 2018;93:385–390.
   PubMed Web of Science ®Google Scholar
• Narang T, Kumar S, Handa S, et al. Hydroxyurea and Acitretin as a novel combination therapy in severe plaque psoriasis. Br J Dermatol. 2018 Jun:21. doi: 10.1111/bjd.16899. [Epub ahead of print].
   PubMedGoogle Scholar
• Uray IP, Dmitrovsky E, Brown PH. Retinoids and rexinoids in cancer prevention: from laboratory to clinic. Semin Oncol. 2016 Feb;43:49–64.
   PubMed Web of Science ®Google Scholar
• Raone B, Patrizi A, Gurioli C, et al. Cutaneous carcinogenic risk evaluation in 375 patients treated with narrowband-UVB phototherapy: a 15-year experience from our Institute. Photodermatol Photoimmunol Photomed. 2018 Mar 13. doi: 10.1111/phpp.12382. [Epub ahead of print].
   PubMedGoogle Scholar
• Dogra S, Jain A, Kanwar AJ. Efficacy and safety of acitretin in three fixed doses of 25, 35 and 50 mg in adult patients with severe plaque type psoriasis: a randomized, double blind, parallel group, dose ranging study. J Eur Acad Dermatol Venereology. 2013 Mar;27:e305–11.
   PubMed Web of Science ®Google Scholar
• McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Safety. 2002;25:913–927.
   PubMed Web of Science ®Google Scholar
• Svendsen MT, Andersen F, Andersen KH, et al. Can an app supporting psoriasis patients improve adherence to topical treatment? A single-blind randomized controlled trial. BMC Dermatol. 2018 Feb 7;18:2.
   PubMed Web of Science ®Google Scholar